top of page

Free Biopharma Daily Stock Updates - 01/06/22

$XBI $105.20 -0.03% %

 

Covid Updates

$COCP -3.1% Cocrystal Pharma Receives FDA Guidance to Advance Clinical Development of its COVID-19 Antiviral CDI-45205 source




Pipeline Updates

$KNTE -5.1% Kinnate Biopharma Inc. Provides Corporate Update and Highlights Key Upcoming 2022 Milestones source


$FDMT -0.2% 4D Molecular Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial of 4D-150, a Dual-Transgene Intravitreal Gene Therapy for Patients with wet AMD source


$RFL +3.2% Rafael Pharmaceuticals Announces Successful Completion of Dose Escalation with No Dose-Limiting Toxicity (DLT) in First Cohort of APOLLO 613 Phase 1/2 Clinical Trial of CPI-613® (Devimistat) in Patients with Relapsed Clear Cell Sarcoma source


$PCVX +3.1% Vaxcyte Announces FDA Clearance of Investigational New Drug Application for VAX-24 for the Prevention of Invasive Pneumococcal Disease source


$EIGR 0.0% Eiger BioPharmaceuticals Announces Outlook and Planned 2022 Catalysts and Milestones source


$RLYB +6.8% Rallybio Highlights Portfolio Advances and Outlines Expected Upcoming Milestones for 2022 source


$ALGS -56.7% Aligos Halting Further Development of STOPS™ Drug Candidate, ALG-010133 source


$BOLT -11.0% Bolt Biotherapeutics Doses First Patient with BDC-1001 in Combination with OPDIVO® (nivolumab) in Ongoing Phase 1/2 Clinical Trial for the Treatment of HER2-Expressing Solid Tumors source


$AXLA +1.0% Axcella Therapeutics Details Clinical and Operational Milestones for 2022 source


$OTIC +1.5% Otonomy Reports Corporate and Product Pipeline Update source


$APTX +2.7% Aptinyx Highlights Key Goals and Anticipated Development Milestones for 2022 source


$NTLA +1.2% Intellia Therapeutics Highlights Strategic Priorities and Anticipated Development Milestones for 2022 source


$AVTX -31.3% Avalo Reports Positive Phase 1b Results for AVTX-002 in Moderate to Severe Crohn's Disease Patients and Presents Additional Program Updates at 2022 Investor Event source


$RGNX -0.5% REGENXBIO ANNOUNCES FDA CLEARANCE OF IND FOR CLINICAL TRIAL OF RGX-202, A NOVEL GENE THERAPY CANDIDATE FOR DUCHENNE MUSCULAR DYSTROPHY source


$OBSV -2.9% ObsEva Announces Positive Topline Results for Linzagolix 200 mg with Add-Back Therapy in the Phase 3 EDELWEISS 3 Trial in Patients with Moderate-to-Severe Endometriosis-Associated Pain source


$SYBX -0.9% Synlogic Announces Progress Toward 2022 Clinical Milestones and Participation at Upcoming Investor Conferences source


$INAB +3.4% IN8bio Announces Clinical Updates from the Phase 1 Clinical Trial of its Genetically Modified Gamma-Delta T Cell Therapy in Newly Diagnosed Glioblastoma Multiforme source


$PSTV +2.3% PLUS THERAPEUTICS SIGNIFICANTLY EXPANDS INVESTIGATIONAL ONCOLOGY DRUG PIPELINE source


$CRIS -27.6% Curis Announces Updated Data with Additional Encouraging Clinical Activity in Phase 1/2 Study of CA-4948 Monotherapy in Targeted Patients with Relapsed or Refractory AML and MDS; and Initial Clinical Data from Phase 1 Study of CI-8993 in Patients with Relapsed or Refractory Solid Tumors source


$AFMD +1.4% AFFIMED ANNOUNCES COMPLETION OF ENROLLMENT IN REDIRECT, THE REGISTRATION-DIRECTED STUDY OF AFM13 IN PTCL, AND PROVIDES BUSINESS UPDATE source



Business Updates

$RDHL 0.0% RedHill Biopharma and Gaelan Medical Enter Into License Agreement for Talicia® for the United Arab Emirates source




 

Posted by JM

0 comments
bottom of page